肝線維症治療薬市場：薬剤タイプ別、流通チャネル別-2025-2030年の世界予測

肝線維症治療薬市場は、2023年に142億8,000万米ドルと評価され、2024年には155億7,000万米ドルに達すると予測され、CAGR 9.74％で成長し、2030年には273億8,000万米ドルに達すると予測されています。

肝線維症治療薬市場の範囲は、細胞外マトリックスタンパク質の過剰蓄積を特徴とし、瘢痕組織の形成と肝機能の悪化をもたらす肝線維症の治療を目的とした治療薬の開発、生産、流通を包含します。医療技術の進歩に伴い、肝炎、肝硬変、非アルコール性脂肪性肝炎（NASH）などの肝疾患の増加により、効果的な肝線維症治療薬の必要性が高まっています。これらの治療法は、病院、診療所、研究機関など、さまざまな最終用途分野に適用され、症状を管理し、病気の進行を遅らせ、患者の予後を改善します。市場成長に影響を与える主な要因としては、ライフスタイルの変化、飲酒、高齢化による肝疾患の有病率の上昇、ヘルスケアにおける研究開発に対する政府および民間部門の資金提供の増加などが挙げられます。しかし、医薬品開発コストの高さ、規制の厳しさ、現在の治療法の有効性の限界といった課題が市場開拓の妨げとなっています。こうした制約は、特に精密医療とバイオテクノロジーの進歩を活用した、コスト効率が高く効果的な治療ソリューションの開発において、技術革新の機会を浮き彫りにしています。製薬企業と研究機関の連携強化により、新規創薬ターゲットやドラッグデリバリーシステムの発見が加速する可能性があります。さらに、個別化医療に対する需要の高まりは、オーダーメイドの治療計画の可能性を提示し、肝線維症のより効果的な管理を促進します。こうした機会を活用するため、企業は研究開発や戦略的パートナーシップに投資し、臨床試験を進め、承認プロセスを迅速化する必要があります。市場がダイナミックで競合が激しいという性質上、アンメット・メディカル・ニーズに応えるための継続的な技術革新が必要となります。一方、新興地域はヘルスケア・インフラと患者基盤が拡大しているため、拡大の機会があります。啓発キャンペーンや肝臓の健康に関する教育を通じて利害関係者を巻き込むことで、市場への浸透と新製品の受容を促進することもできます。

市場力学：急速に進化する肝線維症治療薬市場の主要市場インサイトを公開

肝線維症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の慢性肝疾患の有病率の増加
  • 肝線維症治療に対する有利な償還政策
• 市場抑制要因
  • 肝線維症治療薬の処方と開発の複雑さ
• 市場機会
  • 新規肝線維症治療薬の開発に対する研究費の増加
  • 肝線維症の画像診断技術およびバイオマーカーの向上
• 市場の課題
  • 肝線維症の医薬品承認に関する厳しい規制の枠組み

ポーターのファイブフォース：肝線維症治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肝線維症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、肝線維症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析肝線維症治療薬市場における競合情勢の把握

肝線維症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス肝線維症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肝線維症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨肝線維症治療薬市場における成功への道筋を描く

肝線維症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で慢性肝疾患の罹患率が増加
    • 肝線維症の治療に対する有利な償還政策
  • 抑制要因
    • 肝線維症治療薬の策定と開発の複雑さ
  • 機会
    • 新規開発のための新たな調査資金肝線維症治療薬
    • 肝臓の画像診断技術と肝線維症のバイオマーカーの改善
  • 課題
    • 肝線維症の治療薬承認のための厳格な規制枠組み
• 市場セグメンテーション分析
  • 薬剤の種類：線維症の形成を予防および軽減するための抗線維症薬の使用が増加
  • 流通チャネル：オンライン薬局の24時間年中無休のサービスにより肝線維症治療薬へのアクセスが向上
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肝線維症治療薬市場薬の種類別

• 抗線維化剤
• 抗酸化炎症調節剤
• 抗ウイルス薬
• 免疫調節剤

第7章 肝線維症治療薬市場：流通チャネル別

• オフライン薬局
  • 病院薬局
  • 小売薬局
• オンライン薬局

第8章 南北アメリカの肝線維症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の肝線維症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの肝線維症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • サーボデュタイド第2相試験では、治療を受けた成人の83%がMASHによる肝疾患で画期的な結果を達成し、線維症が大幅に改善したことが示されました。
  • イプセン、米国FDAが希少胆汁うっ滞性肝疾患の治療薬エラフィブラノールの新薬申請を優先審査に指定したことを確認
  • マドリガル・ファーマシューティカルズ、肝線維症を伴うNASHの治療薬レスメチロムの新薬申請のNDA受理と優先審査を発表
• 戦略分析と提言

企業一覧

• Amgen Inc.
• Arbutus Biopharma
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Dicerna Pharmaceuticals, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• FibroGen, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Hepion Pharmaceuticals, Inc.
• Inventiva S.A.
• LG Life Science Ltd.
• Madrigal Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Mirum Pharmaceuticals, Inc.
• Novartis AG
• Pfizer Inc.
• Pharmaxis Limited
• Sanofi SA

LIST OF FIGURES

• FIGURE 1. LIVER FIBROSIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. LIVER FIBROSIS DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LIVER FIBROSIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LIVER FIBROSIS DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIFIBROTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIOXIDANT INFLAMMATION MODULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 28. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 45. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 48. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. INDIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 100. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 112. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. POLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 115. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. QATAR LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
• TABLE 145. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Liver Fibrosis Drugs Market was valued at USD 14.28 billion in 2023, expected to reach USD 15.57 billion in 2024, and is projected to grow at a CAGR of 9.74%, to USD 27.38 billion by 2030.

The scope of the liver fibrosis drugs market encompasses the development, production, and distribution of therapeutic drugs aimed at treating liver fibrosis, a condition characterized by the excessive accumulation of extracellular matrix proteins, leading to scar tissue formation and deteriorating liver function. With advancing medical technology, the necessity for effective liver fibrosis treatments is driven by increasing incidences of liver diseases, such as hepatitis, cirrhosis, and non-alcoholic steatohepatitis (NASH). These therapies are applied across various end-use sectors, including hospitals, clinics, and research institutes, to manage symptoms, slow disease progression, and improve patient outcomes. Key factors influencing market growth include the escalating prevalence of liver diseases due to lifestyle changes, alcohol consumption, and an aging population, alongside increased government and private sector funding for research and development in healthcare. However, challenges such as the high cost of drug development, stringent regulatory hurdles, and limited efficacy of current treatments impede market expansion. These constraints highlight an opportunity for innovation, particularly in developing cost-efficient and effective therapeutic solutions, leveraging advancements in precision medicine and biotechnology. Enhanced collaboration between pharmaceutical companies and research institutions can accelerate the discovery of novel drug targets and delivery systems. Furthermore, the rise in demand for personalized medicine presents potential opportunities for tailored treatment plans, fostering more effective management of liver fibrosis. To capitalize on these opportunities, companies should invest in R&D and strategic partnerships to advance clinical trials and expedite approval processes. The nature of the market, being dynamic and competitive, necessitates continuous innovation to cater to unmet medical needs. Meanwhile, emerging regions offer expansion opportunities, given their growing healthcare infrastructure and patient base. Engaging stakeholders through awareness campaigns and education about liver health can also drive market penetration and acceptance of new products.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liver Fibrosis Drugs Market

The Liver Fibrosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of chronic liver diseases worldwide
  • Favorable reimbursement policies for treatment of liver fibrosis
• Market Restraints
  • Complexity in formulation and development of liver fibrosis drugs
• Market Opportunities
  • Emerging research funding for the development of novel liver fibrosis drugs
  • Improvements in liver imaging techniques and biomarkers for liver fibrosis
• Market Challenges
  • Stringent regulatory frameworks for drug approval of liver fibrosis

Porter's Five Forces: A Strategic Tool for Navigating the Liver Fibrosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liver Fibrosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liver Fibrosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liver Fibrosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liver Fibrosis Drugs Market

A detailed market share analysis in the Liver Fibrosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liver Fibrosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liver Fibrosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liver Fibrosis Drugs Market

A strategic analysis of the Liver Fibrosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liver Fibrosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Arbutus Biopharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hepion Pharmaceuticals, Inc., Inventiva S.A., LG Life Science Ltd., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Mirum Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pharmaxis Limited, and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Liver Fibrosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Antifibrotic Agents, Antioxidant Inflammation Modulators, Antiviral Drugs, and Immune Modulators.
• Based on Distribution Channel, market is studied across Offline Pharmacies and Online Pharmacies. The Offline Pharmacies is further studied across Hospital Pharmacies and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic liver diseases worldwide
    • 5.1.1.2. Favorable reimbursement policies for treatment of liver fibrosis
  • 5.1.2. Restraints
    • 5.1.2.1. Complexity in formulation and development of liver fibrosis drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging research funding for the development of novel liver fibrosis drugs
    • 5.1.3.2. Improvements in liver imaging techniques and biomarkers for liver fibrosis
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory frameworks for drug approval of liver fibrosis
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Growing usage of antifibrotic agents to prevent and reduce the formation of fibrosis
  • 5.2.2. Distribution Channel: Improved access to liver fibrosis drugs due to online pharmacies 24*7 services
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Liver Fibrosis Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Antifibrotic Agents
• 6.3. Antioxidant Inflammation Modulators
• 6.4. Antiviral Drugs
• 6.5. Immune Modulators

7. Liver Fibrosis Drugs Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Offline Pharmacies
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Retail Pharmacies
• 7.3. Online Pharmacies

8. Americas Liver Fibrosis Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Liver Fibrosis Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Liver Fibrosis Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis
  • 11.3.2. Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease
  • 11.3.3. Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Arbutus Biopharma
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Boehringer Ingelheim International GmbH
• 6. Bristol-Myers Squibb Company
• 7. Dicerna Pharmaceuticals, Inc.
• 8. Eli Lilly and Company
• 9. F. Hoffmann-La Roche Ltd.
• 10. FibroGen, Inc.
• 11. Gilead Sciences, Inc.
• 12. GlaxoSmithKline PLC
• 13. Hepion Pharmaceuticals, Inc.
• 14. Inventiva S.A.
• 15. LG Life Science Ltd.
• 16. Madrigal Pharmaceuticals, Inc.
• 17. Merck & Co., Inc.
• 18. Mirum Pharmaceuticals, Inc.
• 19. Novartis AG
• 20. Pfizer Inc.
• 21. Pharmaxis Limited
• 22. Sanofi SA